Clinical Trial Update: The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the effects of BIIL 284 BS on induced sputum variables in patients with asthma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• BIIL 284 BS

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: COMPLETED